Garsorasib is a synthetic small-molecule KRAS G12C inhibitor developed for the treatment of cancers carrying the KRAS G12C mutation. It is also known by the development code D-1553. Garsorasib selectively targets the mutant KRAS G12C protein and inhibits KRAS-dependent signaling pathways involved in tumor-cell proliferation and survival.
Garsorasib is a specialized oncology pharmaceutical active ingredient belonging to the KRAS inhibitor class. It is a chemically synthesized small molecule requiring controlled manufacturing, purification and analytical characterization.
CAS Number: 2559761-14-5
Molecular Formula: C32H32F2N8O2
Molecular Weight: 598.65 g/mol
Development Code: D-1553
Molecule Type: Small Molecule
Drug Class: KRAS Inhibitor
Target: KRAS G12C
Therapeutic Area: Oncology
Garsorasib selectively binds to the mutant KRAS G12C protein and inhibits KRAS G12C-dependent signaling. KRAS is involved in intracellular signaling pathways that regulate cell growth, proliferation and survival. Inhibition of the mutant KRAS G12C pathway can suppress abnormal tumor-cell signaling.
Garsorasib has been developed for the treatment of KRAS G12C-mutated solid tumors, particularly advanced non-small-cell lung cancer (NSCLC). It has also been investigated in other KRAS G12C-mutated cancers, including colorectal cancer.
KRAS G12C is a specific oncogenic mutation found in several cancers. Garsorasib was designed to selectively inhibit this mutated form of KRAS rather than broadly inhibiting normal cellular signaling.
Garsorasib is a synthetic small molecule with the molecular formula C32H32F2N8O2 and molecular weight 598.65 g/mol. It has two defined stereocenters and is electrically neutral.
Garsorasib API quality evaluation may include identity by IR/HPLC/LC-MS, assay by HPLC, related substances, residual solvents, water content, residue on ignition, elemental impurities and other applicable pharmaceutical quality-control tests.
Garsorasib should be stored in a tightly closed container under controlled pharmaceutical storage conditions and protected from excessive heat, moisture and direct light. Final storage requirements should follow validated stability data and the applicable product-specific specification.
Garsorasib has been evaluated as an orally available KRAS G12C inhibitor in clinical studies involving KRAS G12C-mutated cancers. Its development code is D-1553, and its chemical identity is documented by FDA GSRS and PubChem.
Garsorasib is a synthetic KRAS G12C inhibitor with CAS Number 2559761-14-5, molecular formula C32H32F2N8O2, and molecular weight 598.65 g/mol. It is also known as D-1553 and is an oncology-focused small-molecule API.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Water Content | NMT 1.0% |